Valuation: Arcus Biosciences, Inc.

Market Cap 380.46Cr 333.7Cr 308.08Cr 284.7Cr 539.62Cr 36TCr 550.42Cr 3.7TCr 1.44TCr 18TCr 1.43TCr 1.4TCr 62TCr P/E 2026 *
-8.23x
P/E 2027 * -8.97x
Enterprise Value 318.33Cr 279.21Cr 257.77Cr 238.2Cr 451.49Cr 30TCr 460.53Cr 3.1TCr 1.2TCr 15TCr 1.2TCr 1.17TCr 52TCr EV / Sales 2026 *
37.4x
EV / Sales 2027 * 38.1x
Free-Float
70.85%
Yield 2026 *
-
Yield 2027 * -
1 day-1.74%
1 week+2.42%
Current month-3.92%
1 month+27.02%
3 months+30.77%
6 months+38.74%
Current year+24.30%
1 week 28.9
Extreme 28.9
31.23
1 month 21.84
Extreme 21.84
31.74
Current year 18.52
Extreme 18.515
31.74
1 year 8.57
Extreme 8.57
31.74
3 years 6.5
Extreme 6.5
31.74
5 years 6.5
Extreme 6.5
49.1
10 years 6.3
Extreme 6.3
49.1
Manager TitleAgeSince
President 68 01/05/2015
Chief Executive Officer 67 01/05/2015
Director of Finance/CFO 53 01/08/2020
Director TitleAgeSince
Chairman 67 01/12/2017
Director/Board Member 65 18/09/2017
Director/Board Member 71 01/05/2015
Date Insider Type Main position Quantity % Market Cap.
24/06Sell

Founder

-6,431 0.0051%
11/06Free

Director

22,600 0.0180%
11/06Free

Director

22,600 0.0180%
Change 5-day change 1-year change 3-year change Capi.($)
-1.75%+2.42%+248.47%+35.37% 380.46Cr
-0.24%+1.85%+3.13%+8.40% 4.97TCr
-0.54%+0.72%+418.28%+594.08% 4.05TCr
-2.91%+3.27%+22.82%+55.95% 3.43TCr
-3.01%-0.77%+22.60%-8.11% 3.48TCr
-0.79%+2.02%+3.83%+36.42% 2.7TCr
+2.94%+2.94% - - 1.66TCr
-4.21%-3.73%+62.26%+116.43% 1.56TCr
-2.35%+6.18%+103.40%+101.26% 1.43TCr
-2.70%-2.04%+12.37%+17.77% 1.38TCr
Average -1.65%+3.40%+99.68%+106.40% 2.5TCr
Weighted average by Cap. -1.62%+4.27%+95.51%+131.49%

Financials

2026 *2027 *
Net sales 8.51Cr 7.46Cr 6.89Cr 6.37Cr 12Cr 814.47Cr 12Cr 83Cr 32Cr 398.57Cr 32Cr 31Cr 1.38TCr 9.31Cr 8.16Cr 7.54Cr 6.96Cr 13Cr 891.04Cr 13Cr 91Cr 35Cr 436.04Cr 35Cr 34Cr 1.51TCr
Net income -46Cr -40Cr -37Cr -34Cr -65Cr -4.37TCr -66Cr -444.27Cr -172.62Cr -2.14TCr -171.38Cr -167.63Cr -7.42TCr -43Cr -38Cr -35Cr -32Cr -61Cr -4.12TCr -62Cr -419.11Cr -162.84Cr -2.02TCr -161.68Cr -158.13Cr -7TCr
Net Debt -62Cr -54Cr -50Cr -46Cr -88Cr -5.95TCr -90Cr -604.84Cr -235.01Cr -2.91TCr -233.33Cr -228.22Cr -10TCr -26Cr -23Cr -21Cr -19Cr -37Cr -2.48TCr -38Cr -252.47Cr -98Cr -1.22TCr -97Cr -95Cr -4.22TCr
Logo Arcus Biosciences, Inc.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Employees
601
Date Price Change Volume
08/26/08 $29.61 -2.12% 2,31,946
07/26/07 $30.25 +0.90% 7,94,369
06/26/06 $29.98 -1.15% 7,62,037
02/26/02 $30.33 +4.88% 13,25,784
01/26/01 $28.92 -6.20% 16,64,831
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
30.25USD
Average target price
35.75USD
Spread / Average Target
+18.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RCUS Stock